In the 2016 OPPS, did CMS authorize add-on payments for any other drugs than the one you mentioned last week—bilatumonmab? 


The Centers for Medicare & Medicaid Services (CMS) did not authorize fiscal year 2016 add-on payments for isavuconazonium sulfate, a drug that the Food & Drug Administration (FDA) approved last March for the treatment of invasive fungal infections.

In addition, CMS discontinued add-on payments for glucarpidase but retained the payments for Kcentra prothrombin complex concentrate. The FY 2016 maximum add-on payment for Kcentra is $1,587.50 per case. Both biologics were eligible for the payments during FY 2015.


CPT® copyright 2021 American Medical Association (AMA). All rights reserved.

Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.

CPT is a registered trademark of the American Medical Association.